Estimation of telomerase, AFP, and AFP-L3 levels in Sudanese patients with hepatocellular carcinoma and chronic liver diseases
Telomerase enzyme activity is considered a widespread and relatively selective tumor cell marker feature that can be used for detecting the presence of various neoplastic cells. The positive activity of telomerase enzyme was also recorded in chronic liver disease and is evaluated as a more appropriate biomarker for differentiating hepatocellular carcinoma (HCC) from chronic liver diseases. The current study aimed to evaluate telomerase, AFP, and AFP-L3 levels in Sudanese patients with hepatocellular carcinoma and chronic liver diseases. The study enrolled 113 patients: HCC (n = 33), cirrhosis (n = 33), and chronic hepatitis (n = 47), jointly with 50 healthy controls. Enzyme-linked immunosorbent assay (ELISA) technique was used to estimate the telomerase, AFP, and AFP-L3 levels in blood samples. The telomerase level was elevated in 70% of HCC patients, and it was significantly higher in HCC patients compared to that in healthy controls (1.38 versus 0.35 ng/ml, respectively; P < 0.01). Serum alpha-fetoprotein (AFP) and Lens culinaris agglutinin-reactive (AFP-L3) levels were also significantly elevated in HCC patients compared to healthy controls (130.76 versus 5.59 ng/ml; P < 0.01) and (59.76 versus 0.49 ng/ml; P < 0.01), respectively. The combination between telomerase and AFP or AFPL-3 lead to increased telomerase sensitivity (85 and 79%, respectively).Telomerase was found to be further sensitive in patients with a tumor size of less than 5 cm as well as to tumors of more than 5 cm. Two healthy control samples showed an increase in telomerase level. The combined use of telomerase, AFP, and AFP-L3 levels might be useful for achieving better sensitivity for HCC patients.
KeywordsHepatocellular carcinoma ELISA telomerase cirrhosis Chronic hepatitis
Special thanks to Dr. Abdelbagi Ahmed for helping with the statistical analysis. We are grateful to the director and staff of Molecular Biology Laboratory, Faculty of Medical Laboratory Sciences, Alneelain University, for providing lab facilities.
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Compliance with ethical standards
All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all4966 individual participants included in the study.
- Abdel Hady A, El Shanawany F, Hassan MM, Anas A, Mostafa I, Abdel Hadi A (2010) Evaluation of human telomerase activity as a novel tumor marker for hepatocellular carcinoma. Life Sci J 7(4):153–161Google Scholar
- American Federation for Aging Research (AFAR) (2011) Info-aging Guide to Telomeres and Telomerase. New York, Biol Aging 1–7Google Scholar
- El-Garem H, Khayyal AA, Mosa TE, Ramadan A (2010) Telomerase activity in hepatocellular carcinoma and chronic hepatitis C virus. J Genet Eng Biotechnol 8(1):81–87Google Scholar
- Emad IA, Samir MA, Emad EFI, Mohamad TM, Taher IES (2002) Assaying telomerase activity in three different malignant condition in Egyptian patients employing the polymerase chain reaction technique. J Egypt Nat Cancer Inst 14(3):229–236Google Scholar
- Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, Rapaccini G, Del Poggio P, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Bernardi M, Trevisani F (2006) Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 101(3):524–532CrossRefPubMedGoogle Scholar
- Heaphy CM, Subhawong AP, Hong SM, Goggins MG, Montgomery EA, Gabrielson E, Netto GJ, Epstein JI, Lotan TL, Westra WH, Shih IM, Iacobuzio-Donahue CA, Maitra A, Li QK, Eberhart CG, Taube JM, Rakheja D, Kurman RJ, Wu TC, Roden RB, Argani P, de Marzo AM, Terracciano L, Torbenson M, Meeker AK (2011) Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol 179(4):1608–1615CrossRefPubMedPubMedCentralGoogle Scholar
- Huang FC, Chang CC, Lou PJ, Kuo IC, Chien CW, Chen CT, Shieh FY, Chang TC, Lin JJ (2008) G-quadruplex stabilizer 3,6-bis (1-methyl-4-vinylpyridinium) carbazolediiodide induces accelerated senescence and inhibits tumorigenic properties in cancer cells. Mol Cancer Res 6(6):955–964CrossRefPubMedGoogle Scholar
- Johnson PJ, Pirrie SJ, Cox TF, Berhane S, Teng M, Palmer D, Morse J, Hull D, Patman G, Kagebayashi C, Hussain S, Graham J, Reeves H, Satomura S (2014) The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomark Prev 23(1):144–153CrossRefGoogle Scholar
- Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, Harnois D, Llovet JM, Normolle D, Dalhgren J, Chia D, Lok AS, Wagner PD, Srivastava S, Schwartz M (2009) Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 137(1):110–118CrossRefPubMedPubMedCentralGoogle Scholar
- Miura N, Maruyama S, Oyama K, Horie Y, Kohno M, Noma E, Sakaguchi S, Nagashima M, Kudo M, Kishimoto Y, Kawasaki H, Hasegawa J, Shiota G (2007) Development of a novel assay to quantify serum human telomerase reverse transcriptase messenger RNA and its significance as a tumor marker for hepatocellular carcinoma. Oncology 72(1):45–51CrossRefPubMedGoogle Scholar
- Pathak S, Risin S, Brown N, Berry K (1994) Telomeric association of chromosomes is an early manifestation of programmed cell-death.Int. J Oncol 4(2):323–328Google Scholar
- Shata YM, Mudawi S, Fedail SS, Al Abd BH, Ismaeil AM, Ahmed SM (2014) Assessment of Lens culinaris agglutinin-reactive fraction of alpha fetoprotein as an early diagnostic marker for hepatocellular carcinoma among Sudanese patients with chronic liver disease. Cancer Oncol Res 2(1):1–6Google Scholar
- Tahtouh R, Azzi AS, Alaaeddine N, Chamat S, Bouharoun-Tayoun H, Wardi L et al (2015) Telomerase inhibition decreases alpha-fetoprotein expression and secretion by hepatocellular carcinoma cell lines: in vitro and in vivo study. PLoS One 10(10):e0119512. https://doi.org/10.1371/journal.pone.0119512 CrossRefPubMedPubMedCentralGoogle Scholar
- Yao DF, Dong ZZ, Yao M (2007) Specific molecular markers in HCC. Hepatobiliary Pancreat Dis Int 6(3):15–22Google Scholar
- Yao DF, Wu W, Yao M, Qiu LW, Wu XH, Su XQ et al (2006) Dynamic alteration of telomeraseexpression and its diagnostic significance in liver or peripheral blood for hepatocellular carcinoma. World J Gastroenterol 12(31):4966–4972Google Scholar